TFS
  • TFS
  • Quotes
  • Change country
    • France
  • Share:
  • Subscribe:
  • news.cision.com/
  • TFS
US/UK/Canada
  • US/UK/Canada
  • France

Share

Quotes

In spearheading our adoption of Medidata Detect, we're not only reinforcing our commitment to data quality and patient safety, but we're also embracing a pivotal enhancement to our existing technology stack. Our partnership with Medidata now extends beyond the realms of Rave® EDC, CTMS, and eTMF, illustrating a significant step in our long-term strategy to advance clinical trial efficiency through innovation.
Michael Mendoza, Executive Director of eClinical Technology and Biometrics, TFS HealthScience
We are thrilled to be the first CRO implementing Medidata’s Detect platform, which addresses many data inefficiencies the industry experiences today. Using a centralized data management system will enhance data quality, risk management, and decision-making, fast-tracking clinical trials for clients and the availability of drugs for patients.
Dr. Bassem Saleh, Chief Executive Officer, TFS HealthScience
At Medidata, we’re collaborating with our 2,300+ global customers to accelerate clinical trials by developing new, scalable data experiences that improve quality, maximize efficiency, and better support patients. Medidata Detect will give TFS HealthScience a competitive advantage with AI-driven insights and task automation that reduce the time to high-quality data and bring operational teams closer, eliminating redundancies and aligning processes across the organization.
Tom Doyle, Chief Technology Officer, Medidata
Pick a time period -
Tags ( Active)

TFS presents TrialOnline - digital solution for patient retention and data collection as an example of a successful industry partnership.

Mon, Mar 09, 2020 08:50 CET

TFS attends ADCM Conference to present a TrialOnline ePRO – a custom patient retention tool developed in successful partnership between a CRO, EDC vendor and pharma. Patient retention represents an important challenge in some therapeutic areas. Many clinical trials are at risk a risk of low patient retention putting study at jeopardy, may be destined to fail due to a low patient retention. In example, the prevalence of chronic psoriasis in Western industrialized countries is around 2% (>30M people). Most treatments have side effects that may lead patients to withdrawn the treatment,

There are no items matching the current filter
There are no more items matching the current filter
Back to top
©Cision
Privacy statement | Cookies | About | Content Policy | Contact    Cision
©Cision Privacy statement Cookies About Content Policy Contact

   Cision